dipyridamole has been researched along with Dyslipidemia in 2 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baroncini, LAV | 1 |
| Précoma, LB | 1 |
| Busato, CD | 1 |
| Monclaro, M | 1 |
| Neto, DP | 1 |
| Alessi, A | 1 |
| Précoma, DB | 1 |
| Liao, JK | 1 |
1 review available for dipyridamole and Dyslipidemia
| Article | Year |
|---|---|
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr | 2007 |
1 other study available for dipyridamole and Dyslipidemia
| Article | Year |
|---|---|
Risk stratification by accelerated high-dose dipyridamole stress echocardiography in patients over 70 years of age.
Topics: Age Factors; Aged; Aged, 80 and over; Coronary Artery Disease; Dipyridamole; Dyslipidemias; Echocard | 2013 |